Jia Yi, Dwivedi Alok, Elhanafi Sherif, Ortiz Arleen, Othman Mohamed, Zuckerman Marc
Division of Gastroenterology, Texas Tech University Health Sciences Center, El Paso, Texas, USA.
Division of Biostatistics & Epidemiology, Texas Tech University Health Sciences Center, El Paso, Texas, USA.
Endosc Int Open. 2015 Oct;3(5):E409-17. doi: 10.1055/s-0034-1392552. Epub 2015 Aug 11.
Endoscopic variceal ligation (EVL) and endoscopic variceal sclerotherapy (EVS) are the main therapeutic procedures for the emergency treatment and secondary prophylaxis of esophageal varices in cirrhotics. Post-endoscopic bacteremia has been reported after EVS and EVL, but data on the frequency of bacteremia are conflicting. This study aims to provide incidences of bacteremia after EVS and EVL in different settings through meta-analysis.
Only prospective or randomized studies were included in this meta-analysis. Binomial distribution was used to compute variance for each study. Random effects models were used as the final model for estimating the effect size and 95 % confidence interval. Adjusted effects were obtained using meta-regression analysis.
Nineteen prospective studies involving 1001 procedures in 587 patients were included in the meta-analysis on the risk of bacteremia after EVS or EVL in cirrhotics with esophageal varices. The frequency of bacteremia after endoscopic variceal therapy was 13 %. The frequency of bacteremia after EVS (17 %) was higher than after EVL (6 %) with no statistically significant difference (P = 0.106). The frequency of bacteremia after elective EVS (14 %) was significantly less than after emergency EVS (22 %) (P < 0.001). The frequency of bacteremia after elective EVL (7.6 %) was not significantly different from after emergency EVL (3.2 %) (P = 0.850).
The incidence of bacteremia is low in patients with cirrhosis and varices after esophageal variceal therapy. These results are consistent with our current guidelines that antibiotic prophylaxis before endoscopic variceal therapy is only necessary for bleeding patients.
内镜下静脉曲张套扎术(EVL)和内镜下静脉曲张硬化疗法(EVS)是肝硬化患者食管静脉曲张急诊治疗和二级预防的主要治疗手段。EVS和EVL术后均有内镜后菌血症的报道,但关于菌血症发生率的数据存在冲突。本研究旨在通过荟萃分析提供不同情况下EVS和EVL术后菌血症的发生率。
本荟萃分析仅纳入前瞻性或随机研究。采用二项分布计算每项研究的方差。随机效应模型作为估计效应大小和95%置信区间的最终模型。使用荟萃回归分析获得校正效应。
19项前瞻性研究纳入了本次荟萃分析,涉及587例患者的1001例手术,研究对象为患有食管静脉曲张的肝硬化患者EVS或EVL术后菌血症风险。内镜下静脉曲张治疗后菌血症的发生率为13%。EVS术后菌血症发生率(17%)高于EVL术后(6%),但差异无统计学意义(P = 0.106)。择期EVS术后菌血症发生率(14%)显著低于急诊EVS术后(22%)(P < 0.001)。择期EVL术后菌血症发生率(7.6%)与急诊EVL术后(3.2%)差异无统计学意义(P = 0.850)。
食管静脉曲张治疗后,肝硬化和静脉曲张患者菌血症的发生率较低。这些结果与我们目前的指南一致,即内镜下静脉曲张治疗前仅对出血患者有必要进行抗生素预防。